Char

Character Biosciences is a precision medicine company focused on developing targeted therapies for polygenic diseases, with an initial emphasis on progressive eye conditions such as age-related macular degeneration (AMD) and glaucoma. The company leverages a proprietary platform that integrates deep genomic data with longitudinal clinical records, imaging, and AI-enabled biomarker quantification to identify genetic drivers of disease progression. By characterizing patient subtypes, Character Bio aims to match individual patients with specific medicines that address the underlying drivers of their disease. Their lead programs include CTX203, a lipid-modulating peptide for AMD, and CTX114, a complement inhibitor designed to protect retinal surfaces. The company's approach seeks to move beyond one-size-fits-all treatments toward more effective, personalized interventions for complex genetic disorders.